These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 7594331)

  • 21. Preventive effects of lansoprazole and famotidine on gastric mucosal injury induced by low-dose aspirin in Helicobacter pylori-negative healthy volunteers.
    Nishino M; Sugimoto M; Kodaira C; Yamade M; Uotani T; Shirai N; Ikuma M; Tanaka T; Sugimura H; Hishida A; Furuta T
    J Clin Pharmacol; 2011 Jul; 51(7):1079-86. PubMed ID: 20663999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of rabeprazole alone or in combination with H2 receptor blocker on intragastric pH: a pilot study.
    Törüner M; Bektaş M; Cetinkaya H; Soykan I; Ozden A
    Turk J Gastroenterol; 2004 Dec; 15(4):225-8. PubMed ID: 16249975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of 24-hour intragastric pH using four liquid formulations of lansoprazole and omeprazole.
    Sharma VK
    Am J Health Syst Pharm; 1999 Dec; 56(23 Suppl 4):S18-21. PubMed ID: 10597120
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of a proton pump inhibitor AG-1749 (lansoprazole) on intragastric pH: 24-hour intragastric pH monitoring].
    Kihira K; Yoshida Y; Kasano T; Taniguchi Y; Sato K; Kimura K; Hirose M; Koyama H
    Nihon Shokakibyo Gakkai Zasshi; 1991 Mar; 88(3):672-80. PubMed ID: 1646341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Usefulness of every-other day administration of proton pump inhibitors from the standpoint of continuous 48-hour pH measurements-- Comparison of cimetidine, omeprazole, and lansoprazole].
    Yamamoto Y; Sezai S; Sakurabayashi S; Hirano M; Oka H
    Nihon Shokakibyo Gakkai Zasshi; 1995 Jun; 92(6):919-24. PubMed ID: 7609313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of lansoprazole and famotidine for gastric acid inhibition during the daytime and night-time in different CYP2C19 genotype groups.
    Shirai N; Furuta T; Xiao F; Kajimura M; Hanai H; Ohashi K; Ishizaki T
    Aliment Pharmacol Ther; 2002 Apr; 16(4):837-46. PubMed ID: 11929404
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Twenty-four-hour monitoring of intragastric acidity: comparison between lansoprazole 30mg and pantoprazole 40mg.
    Florent C; Forestier S
    Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):195-200. PubMed ID: 9058634
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nasogastric lansoprazole is effective in suppressing gastric acid secretion in critically ill patients.
    Tsai WL; Poon SK; Yu HK; Chang CS; Yeh HZ; Ko CW; Chen GH
    Aliment Pharmacol Ther; 2000 Jan; 14(1):123-7. PubMed ID: 10632655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Morning versus evening dosing of lansoprazole 30 mg daily on twenty-four-hour intragastric acidity in healthy subjects.
    Fraser AG; Sawyerr AM; Hudson M; Smith MS; Pounder RE
    Aliment Pharmacol Ther; 1996 Aug; 10(4):523-7. PubMed ID: 8853755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
    Röhss K; Lind T; Wilder-Smith C
    Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
    Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
    Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of gastric ulcer healing by lansoprazole by measurement of ulcer diameter.
    Aoyama N; Kinoshita Y; Misaki F; Himeno S; Kasuga M; Chiba T
    J Clin Gastroenterol; 1995; 20 Suppl 2():S86-9. PubMed ID: 7594351
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Simplified lansoprazole suspension--a liquid formulation of lansoprazole--effectively suppresses intragastric acidity when administered through a gastrostomy.
    Sharma VK; Vasudeva R; Howden CW
    Am J Gastroenterol; 1999 Jul; 94(7):1813-7. PubMed ID: 10406240
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acid-suppressive efficacy of a reduced dosage of rabeprazole: comparison of 10 mg twice daily rabeprazole with 20 mg twice daily rabeprazole, 30 mg twice daily lansoprazole, and 20 mg twice daily omeprazole by 24-hr intragastric pH-metry.
    Shimatani T; Inoue M; Kuroiwa T; Xu J; Tazuma S; Horikawa Y; Nakamura M
    Dig Dis Sci; 2005 Jul; 50(7):1202-6. PubMed ID: 16047460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
    Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
    Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults.
    Pisegna JR; Sostek MB; Monyak JT; Miner PB
    Aliment Pharmacol Ther; 2008 Mar; 27(6):483-90. PubMed ID: 18162083
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
    Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
    J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of lansoprazole with omeprazole on 24-hour intragastric pH, acid secretion and serum gastrin in healthy volunteers.
    Bruley des Varannes S; Levy P; Lartigue S; Dellatolas F; Lemaire M; Galmiche JP
    Aliment Pharmacol Ther; 1994 Jun; 8(3):309-14. PubMed ID: 7918926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the effect of lansoprazole and omeprazole on intragastric acidity and gastroesophageal reflux in patients with gastroesophageal reflux disease.
    Janczewska I; Sagar M; Sjöstedt S; Hammarlund B; Iwarzon M; Seensalu R
    Scand J Gastroenterol; 1998 Dec; 33(12):1239-43. PubMed ID: 9930385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of intravenous lansoprazole on acute gastric mucosal lesions and acid secretion].
    Inatomi N; Murakami I; Asano S; Inada I; Satoh H
    Nihon Yakurigaku Zasshi; 1996 Dec; 108(6):333-43. PubMed ID: 9017687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.